RE:rndtbl- poster on IVYes, high hsCRP is an important established risk factor for CVD that has been on Resverlogix's radar for a long time now. Perhaps you have forgottem about several of these findings:
1) Apabetalone reduces MACE in post-hoc analysis of patients with elevated CRP @ baseline. See slide 16 of the
January Corporate update.
2) Median hsCRP is 2.8 mg/dL in BETonMACE patients. See the
AHA poster from November 2018.
3) The
Atherosclerosis 2016 paper stated in the discussion "
Elevation of serum inflammatory markers is consistently associated with risk of MACE. In the ASSURE trial, MACE rate was reduced particularly in RVX-208-treated patients with elevated levels of the inflammatory marker CRP (≥2 mg/L) [63]. Thus, RVX-208 may have more favorable effects in the context of systemic inflammation, which is consistent with effects on inflammatory gene expression in liver and whole blood." This paper also measured hsCRP levels in the post-hoc of SUSTAIN and ASSURE but found no differences between treatment groups.
4) Resverlogix presented at
ACC 2014 an abstract titled "
Effects of an apolipoprotein A-1 inducer on progression of coronary atherosclerosis and cardiovascular events in patients with elevated inflammatory markers," which looked at the effects of apabetalone in patients with hsCRP > or < 2 mg/dL.
5) The
Nichols et al paper published last year titled "
Selective BET Protein Inhibition with Apabetalone and Cardiovascular Events: A Pooled Analysis of Trials in Patients with Coronary Artery Disease" included post-hoc MACE analysis of ASSERT/SUSTAIN/ASSURE in those with elevated hsCRP.
6) Inflammation, it's role in CVD and the effect of apabetalone to reduce both has been on the mind of Resverlogix for some time now. Recall the
2017 news release following the publication of Paul Ridker's CANTOS study. SUCCESSFUL CANTOS INFLAMMATION TRIAL SUPPORTS RATIONALE FOR RESVERLOGIX' ONGOING BETONMACE TRIAL.
As for the
JAMA article that rndtbl cited entitled "
Association of Chronic Low-grade Inflammation With Risk of Alzheimer Disease in ApoE4 Carriers"....that is interesting and hopefully anti-inflammatory therapies (such as apabetalone?) can be shown in the clinic to reduce both inflammation and congnitive diseases.
Lastly, you stated "
In your opinion does high CRP elevate HDL levels in the blood above normal levels?" As far as I know, high hsCRP does not elevate HDL levels. That would be a positive correlation. If anything, I would guess that HDL would be inversely correlated with hsCRP such that hsCRP is elevated in those with low HDL.
BearDownAZ